Journal
PROSTATE CANCER AND PROSTATIC DISEASES
Volume 25, Issue 2, Pages 366-369Publisher
SPRINGERNATURE
DOI: 10.1038/s41391-021-00486-2
Keywords
-
Categories
Funding
- Prostate Cancer Foundation
- American Society for Radiation Oncology
- Sylvester Comprehensive Cancer Center
- Department of Defense
Ask authors/readers for more resources
This study found that liver metastases in prostate cancer are associated with poor survival and aggressive genomic features, including MYC amplification, PTEN deletion, and PIK3CB amplification.
Background The site of prostate cancer metastasis is an important predictor of oncologic outcomes, however, the clinicogenomic characteristics associated with the site are not well-defined. Herein, we characterize the genomic alterations associated with the metastatic site of prostate cancer. Methods We analyzed clinical and genomic data from prostate cancer patients with metastatic disease and known metastatic sites from publicly available targeted sequencing data. Results Prostate cancer metastasis to the liver versus other sites of metastasis conferred a high hazard for death in patients with metastatic prostate cancer (HR: 3.96, 95% CI: 2.4-6.5, p < 0.0001). Genomic analysis of metastatic tissues of prostate cancer-specific genes demonstrated that liver metastases were more enriched with MYC amplification (29.5% vs. 9.8%, FDR = 0.001), PTEN deletion (42% vs. 20.8%, FDR = 0.005), and PIK3CB amplification (8.2% vs. 0.9, FDR = 0.005) compared to other sites. No point mutations were significantly associated with liver metastasis compared to other metastatic sites. Conclusion Liver metastases in prostate cancer are associated with poor survival and aggressive genomic features, including MYC-amplification, PTEN-deletion, and PIK3CB-amplification. These findings could have prognostic, treatment, and trial implications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available